First-line treatment of chronic hepatitis B with entecavir or tenofovir in `real-life' settings: from clinical trials to clinical practice

Journal of Viral Hepatitis, 05/18/2012

Two real–life studies of TDF reported response rates of 71–92% after up to 21 months of treatment. Low incidences of drug resistance and favourable tolerabilities were reported for both drugs, thus confirming the results from registration trials.

Print Article Summary